ArticleThe New England journal of medicine2016
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07120828 (The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity), which is not on this map. Cited by 45 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
Who cites it
45 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pre-PCI SGLT2 inhibitors and contrast-induced nephropathy in acute myocardial infarction: A meta-analysis.Medicine · 2025Pooled it
- Safety and efficacy of adjuvant Sotagliflozin therapy in patients with T1D - an update and systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.BMC endocrine disorders · 2024Pooled it
- Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Journal of human hypertension · 2019Pooled it
- Molecular Mechanisms Underlying the Comorbidity of Type 2 Diabetes Mellitus and Coronary Artery Disease: from Insulin Resistance and Inflammation to Endothelial Dysfunction and Therapeutic Implications.Cardiovascular drugs and therapy · 2026Review
- Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.Endocrinology, diabetes & metabolism · 2026Review
- Molecular mechanisms and novel therapeutic targets of diabetic kidney disease.Chinese medical journal · 2026Review
- PAF Triggered Pyroptotic NETosis Aggravates Myocardial Ischemia/Reperfusion Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cardiovascular outcome trials (CVOTs) in cardiorenal metabolic medicine: a decade of transformative progress (2016-2026).Cardiovascular diabetology · 2026Review
- A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome.Nature communications · 2026Article
- Article
- Empagliflozin Alleviates Arsenic Trioxide-Induced Nephrotoxicity by Activating the SIRT1/Akt/Nrf2 Pathway.Journal of toxicology · 2026Article
- Sodium-Glucose Cotransporter 2 Inhibitor Ameliorate Angiotensin II-Induced Hypertension and Vascular Injury by Upregulating FGF21.Inflammation · 2025Article
- Optimizing Bone Health in Diabetes: Strategies for Fracture Risk Reduction in Public Healthcare.Current diabetes reports · 2025Review
- Static training improves insulin resistance in skeletal muscle of type 2 diabetic mice via the IGF-2/IGF-1R pathway.Scientific reports · 2025Article
- SGLT2i Alleviates Atherosclerosis by Inhibiting NHE1 Activation to Protect against Macrophage Senescence Induced by Angiotensin II.Combinatorial chemistry & high throughput screening · 2025Article
- Luteolin improves the systolic and diastolic functions of the thoracic aortic vessels in type 2 diabetic rats through the Kv7.1 channel.Frontiers in pharmacology · 2025Article
- Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population.Current heart failure reports · 2024Review
- Recent advances associated with cardiometabolic remodeling in diabetes-induced heart failure.American journal of physiology. Heart and circulatory physiology · 2024Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26981941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.